EHang Launches UAM Exhibition (Experience) Center in Shenzhen's Luohu District, Showcasing First Automated Smart eVTOL Vertiport for EH216-S
January 21, 2025 23:16 ET
|
EHang Holdings Limited
GUANGZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Urban Air Mobility (“UAM”) technology platform company,...
Coave Therapeutics lève €32 millions d'euros en série A pour accélérer le développement de ses médicaments génétiques de nouvelle génération
January 09, 2025 03:00 ET
|
Coave Therapeutics
Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...
Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines
January 09, 2025 03:00 ET
|
Coave Therapeutics
Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...
ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
January 08, 2025 08:00 ET
|
ViGeneron GmbH
VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis...
ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal Dystrophies
December 18, 2024 08:00 ET
|
ViGeneron GmbH
VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated...
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
December 17, 2024 06:00 ET
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
December 03, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa
December 02, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
October 21, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
EH216-S Pilotless eVTOL Completes First Flight in Brazil
September 24, 2024 10:44 ET
|
EHang Holdings Limited
GUANGZHOU, China, Sept. 24, 2024 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Urban Air Mobility (“UAM”) technology platform company, today...